Androgen regulation in human body
The hypothalamus coordinates many hormonal and behavioural circadian
rhythms, complex patterns of neuroendocrine outputs, complex homeostatic
mechanisms, and important behaviours.
| Gonadotropin-releasing hormone | GnRH or LHRH | Neuroendocrine cells of the Preoptic area | Stimulate follicle-stimulating hormone (FSH) release from anterior pituitary Stimulate luteinizing hormone (LH) release from anterior pituitary |
|---|
 |
Human hypothalamus (animation, shown in red)
courtesy share: http://en.wikipedia.org
|
Pituitary gland is an endocrine gland about the size of a pea and weighing 0.5 grams (0.018 oz) in humans. It is a protrusion off the bottom of the hypothalamus at the base of the brain. The pituitary gland is functionally connected to the hypothalamus by the median eminence via a small tube called the infundibular stem (Pituitary stalk). The pituitary gland secretes nine hormones that regulate homeostasis.
 |
Located at the base of the brain,
the pituitary gland is protected
by a bony structure called the
sella turcica of the sphenoid bone.
courtesy share: http://en.wikipedia.org
|
 |
| Pituitary gland courtesy share: http://en.wikipedia.org |
- Luteinizing hormone (also referred to as 'Lutropin' or 'LH' or, in males, 'Interstitial Cell-Stimulating Hormone' (ICSH))
- Follicle-stimulating hormone (FSH), both released under influence of Gonadotropin-Releasing Hormone (GnRH)
Hormone therapy for adenocarcinoma prostate
Hormone therapy is also called androgen deprivation therapy (ADT) or androgen suppression therapy. The goal is to reduce levels of male hormones, called androgens, in the body, or to prevent them from reaching prostate cancer cells.
The main androgens are testosterone and dihydrotestosterone (DHT).
Androgens, which are made mainly in the testicles, stimulate prostate
cancer cells to grow. Lowering androgen levels or stopping them from
getting into prostate cancer cells often makes prostate cancers shrink
or grow more slowly for a time.
Types of hormone therapy
Several types of hormone therapy can be used to treat prostate cancer.
Orchiectomy (surgical castration)
Even though this is a type of surgery, its
main effect is as a form of hormone therapy. In this operation, the
surgeon removes the testicles (bilateral orchiectomy), where most of the androgens (testosterone
and DHT) are made. With this source removed, most prostate cancers stop
growing or shrink for a time.
GnRH blockers
Gonadotrophin-releasing hormone (GnRH) antagonists (receptor blockers) are a class of compounds that are similar in structure to natural GnRH (a hormone made by neurons in the hypothalamus ) but that have an antagonistic effect. GnRH antagonists are peptide molecules that are made up multiple, often synthetically produced amino acids. GnRH antagonists compete with natural GnRH for binding to GnRH receptors, thus decreasing or blocking GnRH action in the body.
Leuprolide acetate is a synthetic
nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH
or LH-RH). The analog possesses greater potency than the natural hormone. The
chemical name is
5oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide
acetate (salt) with the following structural formula:
 |
| In adults, leuprolide may weaken your bones and increase your risk for bone loss (osteoporosis) if used for a long time because it reduces estrogen... |
Luteinizing hormone-releasing hormone (LHRH) analogs (blockers)
These drugs lower the amount of testosterone made by the testicles. Treatment with these drugs is sometimes called chemical castration because they lower androgen levels just as well as orchiectomy.
Even though LHRH analogs (also called LHRH agonists)
cost more than orchiectomy and require more frequent doctor visits,
most men choose this method. These drugs allow the testicles to remain
in place, but the testicles will shrink over time, and they may even
become too small to feel.
When LHRH analogs are first given, testosterone levels go up briefly before falling to very low levels. This effect is called flare and results from the complex way in which LHRH analogs work.
Anti-androgens
Anti-androgens block the effect of adrenal gland hormone as well as testicular androgens by interfering with a receptor in the nucleus of the prostate cancer cells.
So anti-androgens block the body's ability to use any androgens. Even after orchiectomy or during treatment with LHRH analogs, the adrenal glands still make small amounts of androgens.
So anti-androgens block the body's ability to use any androgens. Even after orchiectomy or during treatment with LHRH analogs, the adrenal glands still make small amounts of androgens.
Drugs of this type, such as flutamide (Eulexin®), bicalutamide (Casodex®), and nilutamide (Nilandron®), are taken daily as pills.
Anti-androgens are not often used by
themselves. An anti-androgen may be added to treatment if orchiectomy or
an LHRH analog is no longer working by itself. An anti-androgen is
sometimes given for a few weeks when an LHRH analog is first started to
prevent a tumor flare.
Anti-androgen treatment may be combined with orchiectomy or LHRH analogs as first-line hormone therapy. This is called combined androgen blockade (CAB).
Duprost is a 5 alpha-reductase enzyme inhibitor. It works by lowering levels of a hormone called dihydrotestosterone (DHT), which is a major cause of prostate growth. Lowering DHT leads to shrinkage of the enlarged prostate gland, reducing the risk of urinary blockage and need for prostate surgery. Duprost (Dutasteride) is used to treat symptoms of benign prostatic hyperplasia.
Silofast (8 mg) - Capsule, manufactured by Cipla Limited contains Generic Medicine Silodosin- 8 mg.Used for the symptomatic treatment of benign prostatic hyperplasia.
Treatment results after the first three month medication as above:
For Post void residual urine volume (PVRUV): changes occurred from 502 cc to 381.53 cc
For weight of the prostate gland: This almost remained the same |
| pre-treatment Ultrasonography studies for 'KUB' dated: 6th July 2013 |
 |
| post-treatment Ultrasonography studies for 'KUB' dated: 17th October 2013 |
For Prostate Specific Antigen, significant change was found as to be in the normal range:
t-PSA from H 75.94 to 1.33 ng/ml
f-PSA from H 7.32 to 0.294 ng/ml |
| pre-treatment 'Prostate Specific Antigen' studies dated: 6th July 2013 |
 |
| post-treatment 'Prostate Specific Antigen' studies dated: 16th October 2013 |
some related blog post
http://en.wikipedia.org
No comments:
Post a Comment